Literature DB >> 10344918

Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.

A J Rosner1, D T Grima, G W Torrance, C Bradley, J D Adachi, R J Sebaldt, D J Willison.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis.
DESIGN: A retrospective, incremental cost-effectiveness analysis was conducted from a societal perspective. It compared 9 treatment strategies over 3 years and incorporated the willingness of patients to initiate and continue each therapy. MAIN OUTCOME MEASURES AND
RESULTS: Four nondominated strategies formed the efficient frontier in the following order: (i) calcium-->no therapy; (ii) ovarian hormone therapy (OHT)-->calcium-->no therapy [166 Canadian dollars ($Can)]; (iii) OHT-->etidronate-->calcium-->no therapy ($Can2331); and (iv) OHT-->alendronate-->calcium-->no therapy ($Can40,965). The figures in parentheses are the incremental costs per vertebral fracture averted to move to that strategy from the previous strategy for patients who had undergone a hysterectomy.
CONCLUSIONS: We identified 4 efficient multi-therapy strategies for the treatment of vertebral osteoporosis in postmenopausal women, 2 of which were consistent with the practice guidelines of the Osteoporosis Society of Canada. Decision-makers may select from among these efficient strategies on the basis of incremental cost effectiveness.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10344918     DOI: 10.2165/00019053-199814050-00007

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  32 in total

Review 1.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

Review 2.  The economics of osteoporosis and its prevention. A review.

Authors:  D J Torgerson; D M Reid
Journal:  Pharmacoeconomics       Date:  1997-02       Impact factor: 4.981

3.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

Review 4.  Meta-analytic tools for medical decision making: a practical guide.

Authors:  V Hasselblad; D C McCrory
Journal:  Med Decis Making       Date:  1995 Jan-Mar       Impact factor: 2.583

5.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

Review 6.  Postmenopausal osteoporosis.

Authors:  S J Silverberg; R Lindsay
Journal:  Med Clin North Am       Date:  1987-01       Impact factor: 5.456

7.  Treatment of postmenopausal osteoporosis with transdermal estrogen.

Authors:  E G Lufkin; H W Wahner; W M O'Fallon; S F Hodgson; M A Kotowicz; A W Lane; H L Judd; R H Caplan; B L Riggs
Journal:  Ann Intern Med       Date:  1992-07-01       Impact factor: 25.391

8.  Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.

Authors:  S T Harris; N B Watts; R D Jackson; H K Genant; R D Wasnich; P Ross; P D Miller; A A Licata; C H Chesnut
Journal:  Am J Med       Date:  1993-12       Impact factor: 4.965

9.  Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis.

Authors:  A B Grey; T F Cundy; I R Reid
Journal:  Clin Endocrinol (Oxf)       Date:  1994-05       Impact factor: 3.478

10.  Cost-effectiveness of hormone replacement therapy in the menopause.

Authors:  M C Weinstein; I Schiff
Journal:  Obstet Gynecol Surv       Date:  1983-08       Impact factor: 2.347

View more
  13 in total

Review 1.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 2.  Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; David J Torgerson
Journal:  Osteoporos Int       Date:  2005-06-25       Impact factor: 4.507

3.  Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis.

Authors:  Rachael L Fleurence; D Eldon Spackman; Christopher Hollenbeak
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Hip fracture prevention: cost-effective strategies.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

5.  Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy.

Authors:  John T Schousboe; Kristine E Ensrud; John A Nyman; Robert L Kane; L Joseph Melton
Journal:  Osteoporos Int       Date:  2005-08-31       Impact factor: 4.507

Review 6.  Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.

Authors:  P Vestergaard; N R Jorgensen; L Mosekilde; P Schwarz
Journal:  Osteoporos Int       Date:  2006-09-02       Impact factor: 4.507

7.  Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries--an economic evaluation based on the fracture intervention trial.

Authors:  O Ström; F Borgström; S S Sen; S Boonen; P Haentjens; O Johnell; J A Kanis
Journal:  Osteoporos Int       Date:  2007-02-28       Impact factor: 4.507

8.  The burden-of-illness study on osteoporosis in the Slovenian female population.

Authors:  Biljana Dzajkovska; Albert I Wertheimer; Ales Mrhar
Journal:  Pharm World Sci       Date:  2007-02-20

Review 9.  The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; Jeanene M Johnson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

10.  Closing the osteoporosis care gap: increased osteoporosis awareness among geriatrics and rehabilitation teams.

Authors:  Derek A Haaland; Dana R Cohen; Courtney C Kennedy; Nader A Khalidi; Jonathan D Adachi; Alexandra Papaioannou
Journal:  BMC Geriatr       Date:  2009-07-14       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.